Questionnaire

1. Among patients with T2DM and at high risk for CVD receiving SGLT-2i therapy, a real-world Danish efficacy study has demonstrated significant reductions in risk for:

2. Steroidal MRAs demonstrate proven efficacy for reducing morbidity and mortality in patients with:

3. The FINEARTS-HF trial of patients with HFmrEF or HFpEF demonstrated consistent cardiovascular benefit of finerenone treatment in participants who:

4. UKPDS follow-up data extending to 24 years demonstrate that early intensive glycaemic control with metformin led to greater overall relative risk reductions than with sulphonylurea or insulin for death and for MI.

5. A residual risk for poor kidney-related outcomes and CVD remains evident in patients with T2DM and CKD and being treated using:

6. The FLOW trial investigating the efficacy of once-weekly semaglutide 1mg plus standard of care in participants with T2DM and CKD (high/very high KDIGO risk) demonstrated significant risk reductions for:

7. A study exploring patterns of progression of kidney disease in a multiethnic cohort of participants found a statistically significant higher risk of progression to advanced CKD stages in black, Indian and mixed-race individuals compared with reference data arising from white individuals with T2DM and CKD.

8. Albuminuria trajectory modelling of Fremantle Diabetes Study data has associated non-normoalbuminuria trajectories in T2DM with:

9. Higher HbA1c variability has been independently associated with progression of DKD in a multiethnic cohort of people with T1DM.

10. The mechanisms whereby dapagliflozin increases CFR in patients with T2DM and stable CAD are related to:

11. The SoliD head-to-head study of suboptimally controlled T2DM using oral antidiabetic drugs found that when compared with IDegAsp, iGlarLixi with continued metformin and SGLT2i resulted in:

12. The IDEAL trial demonstrated that compared with multiple daily insulin regimens, a de-intensification strategy using iGlarLixi provided:

13. ESC/EASL/EASO recommendations for risk stratification and monitoring of MASLD include:

14. Treatments for comorbidities that are contraindicated in cases of decompensated cirrhosis include:

15. Compared to adults with T2DM and youth with T1DM, adolescents with T2DM demonstrate a: